Clinical Trial

Efficacy of Clobetasol Vs Intralesional Triamcinolone in Lichen Planus Treatment

Not Yet Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The purpose of this study is to compare the efficacy and safety of two standard corticosteroid treatments for hypertrophic lichen planus (HLP), a chronic inflammatory skin condition that causes thick, intensely itchy plaques. Patients participating in the study will be randomly assigned to one of two treatment groups: * Group A will apply a superpotent topical steroid cream (Clobetasol propionate 0.05%) to their lesions twice daily for 12 weeks. * Group B will receive intralesional injections of a steroid medication (Triamcinolone acetonide 10 mg/mL) directly into the lesions once every 4 weeks for a total of four sessions over 12 weeks. The primary objective is to determine which approach achieves a better reduction in plaque thickness and severity using the Lichen Planus Severity Index (LPSI) score at week 12. The study will also track changes in itching severity using a Visual Analog Scale (VAS), changes in overall lesion surface area, and monitor for any local side effects such as skin thinning or pigment changes.
Trial Details
NCT Number NCT07666620
Lead Sponsor Noor Aziz
Conditions Hypertrophic Lichen Planus
Enrollment 50 participants
Start Date 2026-10-01
Primary Completion 2027-04-01 (estimated)
Study Completion 2027-04-30 (estimated)
Updated on ClinicalTrials.gov 2026-06-24